Literature DB >> 10686092

Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase.

A Shuaib1, Y Yang, Q Li.   

Abstract

The combination of thrombolysis with neuroprotection, because of different mechanisms, would be expected to show better results when used after onset of focal ischemia. In this study we report our experience with the neuronal protective effects of citicoline alone and in combination with urokinase in a model of focal ischemia. Both medications were injected 2 h after onset of a focal occlusion of the middle cerebral artery (MCA) in rats. Focal ischemia was produced with embolization of a clot into the origin of the MCA. This produces a large infarction involving the cortex and the basal ganglia. Animals were observed for neuronal deficts at 2 and 24 h after surgery and were sacrificed 72 h after onset of ischemia. Saline-treated animals showed a large infarction involving the cerebral cortex and basal ganglion in most animals (volume 33.1 +/- 9.7%). Animals treated with citicoline alone were divided in two groups. The first group of animals were treated with a single injection (300 mg/kg, ip) of the medication 2 h after the arterial occlusion. The second group was treated with the active medication intermittently (3 x 300 mg/kg, ip) over a 72-h period. There was a significant decrease in the neuronal damage in the cortex in the animals treated with citicoline (single dose, 20.9 +/- 9.7%, P = 0.01; intermittent injection, 18.9 +/- 11.4%, P < 0.008). The last experiment evaluated the usefulness of the combination of citicoline with intraarterial urokinase. The combination showed significantly more protection than with urokinase or citicoline alone (volume 13.6 +/- 9.1%, P < 0.001). We conclude from our experiments that citicoline may offer significant neuronal protection that may be further enhanced with the addition of a thrombolytic agent. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10686092     DOI: 10.1006/exnr.1999.7314

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  10 in total

1.  Evaluation of the neuroprotective effects of citicoline after experimental spinal cord injury: improved behavioral and neuroanatomical recovery.

Authors:  Neslihan Yücel; Süleyman R Cayli; Ozkan Ateş; Neşe Karadağ; Serpil Firat; Yusuf Turköz
Journal:  Neurochem Res       Date:  2006-06-21       Impact factor: 3.996

Review 2.  Investigational therapies for ischemic stroke: neuroprotection and neurorecovery.

Authors:  Preeti Sahota; Sean I Savitz
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

3.  Choline kinase β mutant mice exhibit reduced phosphocholine, elevated osteoclast activity, and low bone mass.

Authors:  Jasreen Kular; Jennifer C Tickner; Nathan J Pavlos; Helena M Viola; Tamara Abel; Bay Sie Lim; Xiaohong Yang; Honghui Chen; Robert Cook; Livia C Hool; Ming Hao Zheng; Jiake Xu
Journal:  J Biol Chem       Date:  2014-12-01       Impact factor: 5.157

4.  CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons.

Authors:  Cecilia Mir; Josep Clotet; Rosa Aledo; Núria Durany; Josep Argemí; Rafael Lozano; Jordi Cervós-Navarro; Núria Casals
Journal:  J Mol Neurosci       Date:  2003-02       Impact factor: 3.444

Review 5.  Can the time window for administration of thrombolytics in stroke be increased?

Authors:  Geoffrey A Donnan; David W Howells; Romesh Markus; Danilo Toni; Stephen M Davis
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 6.  Cytidine 5'-diphosphocholine (CDP-choline) in stroke and other CNS disorders.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

Review 7.  Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly.

Authors:  A R Green
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

Review 8.  Pre-clinical to Clinical Translational Failures and Current Status of Clinical Trials in Stroke Therapy: A Brief Review.

Authors:  Neha Dhir; Bikash Medhi; Ajay Prakash; Manoj Kumar Goyal; Manish Modi; Sandeep Mohindra
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 9.  Neurological disorders and therapeutics targeted to surmount the blood-brain barrier.

Authors:  Jagat R Kanwar; Bhasker Sriramoju; Rupinder K Kanwar
Journal:  Int J Nanomedicine       Date:  2012-07-09

Review 10.  Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke.

Authors:  Mikhail Yu Martynov; Eugeny I Gusev
Journal:  J Exp Pharmacol       Date:  2015-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.